Suicidal Risks during Treatment of Bipolar Disorder Patients with Lithium versus Anticonvulsants

 

 Buy Article Permissions and Reprints

The aim of this study was to compare suicidal risks during long-term treatment of bipolar disorder (BPD) patients with lithium versus anticonvulsants (ACs).

Medline^® searching identified 6 reports of direct comparisons of patients diagnosed with BPD by modern criteria, treated ≥6 months with lithium versus ACs (carbamazepine, divalproex, lamotrigine), with non-zero risk of suicide or attempts in at least one study-arm. We extracted rates (events/persons/exposure time) for each treatment arm, and applied random-effects meta-analysis to determine pooled risk ratio, risk difference, and their 95% confidence intervals (CI).

Overall, rates of suicidal acts were 2.86-times (95% CI: 2.29–3.57; p<0.0001) higher during treatment with ACs versus lithium, and no AC emerged as clearly superior to the others.

Comparisons of suicidal risks during treatment with lithium versus ACs remain rare and methodologically limited, but favor lithium and encourage further study in this era of growing regulatory concern about possible adverse effects of ACs.

References

• 1 Ahrens B, Muller-Oerlinghausen B. Does lithium exert and independent antisucidal effect?.  Pharmacopsychiatry. 2001;  34 132-136
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychiatric disorders. Chapters 17 and 18 in: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edition. McGraw-Hill Press, New York 2005: 429-500
  Google Scholar
• 3 Baldessarini RJ, Tondo L. Lithium and suicidal risk.  Bipolar Disord. 2008;  10 114-115
  PubMedGoogle Scholar
• 4 Baldessarini RJ, Tondo L, Davis P. et al . Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review.  Bipolar Disord. 2006;  8 625-639
  Google Scholar
• 5 Baldessarini RJ, Tondo L, Hennen J. Antisuicidal effects of lithium in manic-depressive disorders.  J Clin Psychiatry. 1999;  60 ((Suppl. 2)) 77-84
  PubMedGoogle Scholar
• 6 Bowden CL, Calabrese JR, Sachs G. et al . Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.  Arch Gen Psychiatry. 2003;  60 392-400
  CrossrefPubMedGoogle Scholar
• 7 Calabrese JR, Bowden CL, Sachs G. et al . Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.  J Clin Psychiatry. 2003;  64 1013-1024
  CrossrefPubMedGoogle Scholar
• 8 Collins JC, MacFarland BH. Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.  J Affect Disord. 2008;  107 23-28
  Google Scholar
• 9 Goodwin FK, Fireman B, Simon GE. et al . Suicide risk in bipolar disorder during treatment with lithium and divalproex.  JAMA. 2003;  290 1467-1473
  CrossrefPubMedGoogle Scholar
• 10 Greil W, Ludwig-Mayerhofer W, Erazo N. et al . Lithium vs. carbamazepine in the maintenance treatment of bipolar disorders: randomized study.  J Affect Disord. 1997;  43 151-161
  CrossrefPubMedGoogle Scholar
• 11 Kallner G Lindelius E, Petterson U, Stockman O. et al . Mortality in 497 patients with affective disorders attending a lithium clinic or after having left.  Pharmacopsychiatry. 2000;  33 8-13
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Kessing LV, Søndergård L, Kvist K. et al . Suicide risk in patients treated with lithium.  Arch Gen Psychiatry. 2005;  62 860-866
  CrossrefPubMedGoogle Scholar
• 13 Meltzer HY, Alphs L, Green AI. et al . Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).  Arch Gen Psychiatry. 2003;  60 82-91
  Google Scholar
• 14 Müller-Oerlinghausen B. Pharmacological suicide prevention under special consideration of lithium salts.  Psychiatr Prax. 2007;  34 ((Suppl. 3)) S292-S295
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Simhandl C, Mersch J. Lithium and bipolar disorder – a renaissance?.  Neuropsychiatrie. 2007;  21 121-130
  PubMedGoogle Scholar
• 16 Tondo L, Baldessarini RJ. Risks of suicidal ideation, attempts and suicides among 2 826 men and women with types I and II bipolar, and recurrent major depressive disorders.  Acta Psychiatr Scand. 2007;  116 419-428
  CrossrefPubMedGoogle Scholar
• 17 Tondo L, Baldessarini RJ, Hennen J. et al . Lithium treatment and risk of suicidal behavior in bipolar disorder patients.  J Clin Psychiatry. 1998;  59 405-414
  CrossrefPubMedGoogle Scholar
• 18 Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: Risk and prevention.  CNS Drugs. 2003;  17 491-511
  CrossrefPubMedGoogle Scholar
• 19 US Food and Drug Administration (FDA) . Antiepileptic drugs statistical review and evaluation: Antiepileptic Drugs AEDs) and Suicidality. , Accessed at: http://http.www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4372b1-01-fda.pdf , on 20 August, 2008; 
  PubMed
• 20 Yerevanian BI, Koeka RJ, Mintz J. Lithium, ACs and suicidal behavior in bipolar disorder.  J Affect Disord. 2003;  73 223-228
  CrossrefPubMedGoogle Scholar
• 21 Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior: lithium, divalproex, and carbamazepine.  J Affect Disord. 2007;  103 5-11
  CrossrefPubMedGoogle Scholar

Correspondence

Dr. R. J. Baldessarini

Mailman Research Center 312

McLean Hospital

115 Mill Street

Belmont

MA 02178-9106

USA

Phone: +1/617/855 32 03

Fax: +1/617/855 34 79

Email: rjb@mclean.org